The safety profile observed in the trial was found to be consistent with prior trials, with no safety concerns. Daiichi Sankyo research and development global head Ken Takeshita said ...

Daiichi Sankyo and MSD have announced the first subject ... It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express ...

Merck & Co. and Daiichi Sankyo have pulled an application seeking accelerated Food and Drug Administration approval of one of the drug candidates in their multibillion-dollar collaboration ...

Progress in Lung Cancer Across Daiichi Sankyo’s DXd ADC Portfolio Updated DATROWAY® (datopotamab deruxtecan) combination data across three early-phase trials will be highlighted in patients ...

(RTTNews) - The Biologics License Application (BLA) seeking accelerated approval of patritumab deruxtecan, co-developed by Merck & Co Inc. (MRK) and Daiichi Sankyo Company, Limited (DSKYF ...

IHH Healthcare, supported by Mitsui, has increased its compensation claim against Daiichi Sankyo to $1.3 billion in the Tokyo District Court, related to the Fortis Healthcare acquisition.

(Image/Reuters) Northern TK Venture (NTK), a Singapore-based indirect arm of Malaysia’s IHH Healthcare, has raised its damages claims against Japanese pharma firm Daiichi Sankyo Company by ...

Daiichi Sankyo Co. Ltd. and Merck & Co. Inc. have voluntarily pulled the BLA for accelerated approval tied to their HER3-directed antibody-drug conjugate (ADC) in treating EGFR-mutated non-small-cell ...

May 20 (Reuters) - IHH Healthcare (IHHH.KL), opens new tab said on Tuesday its unit has filed a petition in a Tokyo court to revise damages sought from Japan's Daiichi Sankyo (4568.T), opens new ...

NTK and IHH maintain they have no connection to the Singh brothers and argue that Daiichi Sankyo’s actions were unjustified and damaging. Although the Indian Supreme Court lifted the interim ...

No HER3-targeted drugs have been approved to date, but there are dozens of candidates in clinical testing, so the pressure is on MSD and Daiichi Sankyo to get patritumab deruxtecan to market as ...

IHH Healthcare said on Tuesday its unit has filed a petition in a Tokyo court to revise damages sought from Japan's Daiichi Sankyo over its Fortis Healthcare stake buy to up to 109.3 billion rupees ...